

Please find below and/or attached an Office communication concerning this application or proceeding.

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.usbio.gov

APPLICATION NO JCONTROL NO. 09424815	10 Apr 2000	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION Nibbering		ATTORNEY DOCKET NO. 702-991768
		_		
			EXAMINER	
			Robinson .	
			ART UNIT	PAPER
		_	1653	21

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The previous communication mailed 20 May 2002 is vacated in favor of the following. The period for response commences with the date of mailing of this action.

It is also suggested that all pending claims be reviewed for amendment and cancellation. The claims presented in the preliminary amendment (filed with the application and referred to as replaced during CHAPTER II are present in the application as claims 1 through 26). The preliminary amendment also cancels claims 1-24 (presumed to be claims 1-24 of the above claims 1-26). Please note that this amendment also presents amendment to claims 4-7, 9, 17-20, 22 and 26. Canceled claims cannot be amended. Thus, only claim 26 was amended and new claim 27 was added. In a subsequent amendment (filed 7 Feb 2002) claims 25-27 were canceled and new claims 28-60 were added. Thus, it would appear that only claims 28 to 60 are pending.

The communication filed 7 Feb 2002 is not fully responsive to the Office communication mailed 20 Sep 2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132. The disk appears to have been severely damaged, is unreadable and needs to be replaced.

Since the reply appears to be bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE** (1) **MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- 1. Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. Mailed to:

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

Mailed by Federal Express, United Parcel Service or other delivery service to:
 U. S. Patent and Trademark Office
 2011 South Clark Place
 Customer Window, Box Sequence
 Crystal Plaza Two, Lobby, Room 1B03
 Arlingt n, Virginia 22202

4. Hand Carried directly to the Commer Window at: 2011 South Clark Place
Crystal Plaza Two, Lobby, Ro m 1B03, Box Sequence, Arlington, Virginia 22202

Any inquiry concerning this communication should be directed to Examiner **Hope Robinson**, Art Unit **1653**, whose telephone number is (703) 308-6231. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (703) 308-2923. The fax phone number for the organization where this application or proceeding is assigned is (703) 746-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Chris begins St. Inc.
CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1800

Application No.: <u>09/424,815</u>

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
X	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
П	7. Other:
ц Др	plicant Must Provide:
X	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Εω	rauestions regarding compliance to these requirements, please contact:

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE